Back to top
more

ARK Genomic Revolution ETF: (ARKG)

(Real Time Quote from BATS) As of Nov 19, 2026 01:12 PM ET

$40.65 USD

40.65
2,360,397

-0.61 (-1.48%)

Volume: 2,360,397

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

NA

Zacks News

Sweta Jaiswal, FRM headshot

Biotech ETFs to Shine Bright on Coronavirus Vaccine Progress

AstraZeneca's initiation of a phase III study has heated up competition to bring a coronavirus vaccine to the markets.

Sanghamitra Saha headshot

Top-Performing ETFs of Last Week

Wall Street was moderate last week with the S&P 500 and the Nasdaq gaining about 0.7% and 2.7%, respectively, and the Dow Jones witnessing no movement.

Sweta Killa headshot

5 Sector ETFs That Have Gained More Than 50% This Year

We highlight five ETFs from different sectors of the broad market that have outperformed and gained at least 50% so far this year.

Sweta Jaiswal, FRM headshot

Late-Stage Coronavirus Vaccine Trials Begin: Biotech ETFs to Gain

Two major vaccine developers' entrance into the final stage trials is expected to boost investor optimism.

Sweta Jaiswal, FRM headshot

Biotech ETFs to Gain on Coronavirus Vaccine Progress

The race to find a coronavirus vaccine is heating up as the latest positive data from progress in trials are being published.

Neena Mishra headshot

Can Top ETFs of Q2 Continue to Rally in Q3?

We take a look at the best performing ETFs of Q2 that are likely to gain in Q3 as well.

Sweta Jaiswal, FRM headshot

Biotech ETFs to Shine on Pfizer's Coronavirus Vaccine Progress

Two out of four of Pfizer's coronavirus vaccine candidates, BNT162b1 and BNT162b2, have been granted the 'fast track' designation by the FDA.

Sweta Jaiswal, FRM headshot

Top-Performing Biotechnology ETFs Amid Coronavirus Outbreak

From vaccine-related progress to development of cell therapies for the treatment of coronavirus, all kept the rally in the biotech sector alive.

Sweta Jaiswal, FRM headshot

Biotech ETFs to Gain as Coronavirus Vaccine Hopes Strengthen

As the coronavirus outbreak continues to aggravate, investors are eyeing developments in vaccine or treatments to combat the pandemic.

Sweta Killa headshot

4 Sector ETFs Up More Than 30% in First-Half 2020

We have highlighted four ETFs from various industries that were the star performers in the first half and are likely to continue their outperformance if the current trends continue.